According to the most recent WHO classification of tumors of the CNS, the identification of IDH wild-type GBM relies on the detection of EGFR amplification, TERT promoter mutation, or the simultaneous occurrence of entire chromosome 7 gain and entire chromosome 10 loss (+7/−10) [16] (Table 1). The gene discussed is IDH2; the disease is glioblastoma.